Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Healthcare Collaboration and Partnerships

Sponsored by

Finalist

Abbott's Small Steps to Change programme in collaboration with NHS rheumatologists to implement Treat to Target

Abbott Laboratories in association with DNA Medical Communications


Summary of work

The Treat to Target principles in rheumatoid arthritis include early referral, regular assessment and early diagnosis to make disease remission a realistic target for patients.

Evidence shows that earlier treatment improves patient outcomes. However, access to biologics, if appropriate, is often delayed as they are second‐line treatment and patients are often not reviewed regularly enough or treated to a target, which can make treatment decisions subjective. 

Abbott UK rolled‐out Treat to Target nationally to improve the management of patients, and improve the access to biologics for patients who require this treatment. Partnership with the most influential UK KOLs (including the 2011 European Rheumatology Professional Body (EULAR) chair) led to the inclusion of Treat to Target in the latest SIGN guidance and publication of a consensus on standardising assessment using DAS28 in a peer‐reviewed journal. 

Treat to Target was delivered through a revolutionary programme, Small Steps to Change (SSTC), allowing rheumatologists to break change into small steps, through low-/no-cost solutions delivering target‐driven regimens. SSTC changed routine practice in over 40 units with huge improvements in referral rates (10.76 to two weeks), assessment completion rates (16.7 per cent to 78.9‐100 per cent) and fewer patients with high disease activity at referral (40 per cent vs 25 per cent).

 

 

Executive summary as submitted


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics